Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.
A large-scale shortage of respirators and face shields threatens progress in some labs that are currently trying to ramp up their studies of SARS-CoV-2.